

Date: October 10,2023

To,

The Manager- Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai - 400051

Scrip Code: REMUS

Dear Sir,

Sub: Disclosure under Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2023

Please find enclosed the Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2023. The report has been signed by Mr. Tapan Shah, Company Secretary.

This report is submitted in compliance with Regulation 76 of the SEBI (Depositories and Participants), Regulations, 2018.

This is for your information and records.

Thanking you
Yours faithfully,
For, Remus Pharmaceuticals Limited

Arpit Deepakkumar Shah
Managing Director
DIN:07214641



Encl.: As above

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

USA OFFICE: 5900 Balcones Drive, STE 100 Austin, TX 78731
P: +1 6096 320 320

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

To,
 The Board of Directors,
REMUS PHARMACEUTICALS LIMITED,
 1101 to 1103, South Tower, One 42, B/H Ashok Vatika,
 Nr. Jayantilal Park BRTS,
 Ambli Bopal Road, NA Ahmedabad,
 Ahmedabad-380054 IN.

RECONCILIATION OF SHARE CAPITAL AUDIT

CIN : L24232GJ2015PLC084536
 Authorised Capital : Rs. 2,00,00,000/-

I have examined the Register of Members, beneficiary details given by the Depositories and other records / documents maintained by **M/s. REMUS PHARMACEUTICALS LIMITED**, having its Registered Office at 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054 for issuing Certificate, in accordance with Circular D&CC/FITTC/CIR-16/2002 dated December 31, 2002 issued by Securities and Exchange Board of India (SEBI). To the best of my knowledge and according to the information and explanation given to me and as per the record received through mail and examined by me, I certify that for the quarter ended 30th September, 2023, the details of position of Company's Capital Structure, it's Equity shares position with NSDL, CDSL and Physical, Demat carried out and pending Demat status and other details are as under:

1	For Quarter Ended	30/09/2023
2	ISIN	INE005T01011
3	Face Value	Rs. 10/- per Share
4	Name of the Company	REMUS PHARMACEUTICALS LIMITED
5	Registered Office Address	1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054 IN.
6	Correspondence Address	-- Same as above --
7	Telephone & Fax Nos.	Tel. 079-29999857
8	Email Address	legal@senorespharma.com; remus@remuspharma.com
9	Name of the Stock Exchanges where the Company's Securities are listed with scrip code	The National Stock Exchange of India Ltd. Mumbai – SME emerge market (Symbol- REMUS)
10	Issued Equity Share Capital	No. of Shares 14,73,000



11	Listed Equity Capital (as per company records)		14,73,000				
			No. of shares		% of issued Capital		
12	Held in dematerialized form in NSDL		2,34,475		15.92		
13	Held in dematerialized form in CDSL		12,38,525		84.08		
14	Physical		0		0.00		
15	Total No. of Shares (12+13+14)		14,73,000		100.00		
16	Reason for difference, if any, between (10&11),(11 & 15)		N.A.				
17	Certifying details of changes in share capital during the quarter under consideration as per Table below :						
Particulars	No. of Shares	Applied/ not Applied for Listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimate d to NSDL	In-principle Approval Pending for SE (Specify Names)	
-	-	-	-	-	-	-	
18	Register of Members is updated (YES/NO) if not, updated up to which date			Yes			
19	Reference of previous quarter with regards to excess dematerialized shares, if any			-- N.A. --			
20	Has the company resolved the matter mentioned in point no. 19 above in the current quarter ? If not, reason why ?			-- N.A. --			
21	Mentioned the total no. of requests, confirmed after 21 days and the total no. of requests pending beyond 21 days(in both cases, from the date of DRN & confirmed by the Registrar is taken), with the reasons for delay :						
Total No. of demat requests			No. of requests		No. of shares		Reasons for delay
			NSDL	CDSL	NSDL	CDSL	
Confirmed after 21 days			--	--	--	--	N.A.
Pending for more than 21 Days			--	--	--	--	
22	Name, Telephone & Fax No. of Compliance Officer of the Co.			Ms. Deval Patel , Company Secretary and Compliance office Tel : 079-2999 9857 Email : remus@remuspharma.com			



23	Name, Address, Tel. & Fax No. of the Company Secretary in whole-time practice	Mr. Tapan Shah (CP No.2839) 816-818, Anand Mangal-3, Nr. Doctor House, Ellisbridge, Ahmedabad-6 Tel.& Fax-26430810, 40024320
24	Appointment of Common Agency for Share Registry Work (Name & Address)	Link Intime India Pvt. Ltd. 5th Floor, 506 to 508, Amarnath Business Centre - I (ABC - I), Nr. St. Xavier's College Corner, Off. C.G.Road, Navrangpura, Ahmedabad-380009 Tel-079-26465179
25	Any other detail that the Co. Secretary may like to provide (e.g. BIFR Co., delisting from SE, Company changed its name etc.)	-

Place: Ahmedabad.
Date: 09/10/2023

Signature:  TAPAN RAJNIKANT SHAH
Name of Company Secretary: TAPAN SHAH
C. P. Number: 2839
UDIN: F004476E001228138

Note:

Above report was prepared based on the softcopy of the papers/ report/ documents provided by the Share Registry of the Company, i.e. Link In time Private Ltd.

